Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Viatris Inc filings on SEC EDGAR ↗
Viatris Inc. reported its third quarter 2026 results, highlighting the completion of its OTC business divestiture and the pending acquisition of Pacira BioSciences for $36.50 per share. The company continues to operate through four segments: Developed Markets, Emerging Markets, JANZ, and Greater China, following its 2020 formation via the combination of Mylan and Pfizer's Upjohn business.
Viatris reported Q3 2026 total revenues of $3.75 billion and raised its full-year 2026 financial guidance midpoints across all metrics. The company reported a GAAP net loss of $325.3 million, primarily driven by operational momentum in higher-margin businesses and progress in its innovative medicines strategy, including the pending acquisition of Pacira BioSciences.
Term
Q3 2026
“Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business. Momentum across key areas of our base business, progress in our pipeline and the benefits of our enterprise-wide strategic review continue to strengthen our company.”
Scott A. Smith, CEO, Viatris
“We are very pleased with the operational momentum across our higher-margin businesses and continued focus on cost discipline, which led to strong overall third-quarter results. Based on this performance and our confidence in the outlook for the rest of the year, we are once again raising the midpoints of our financial guidance ranges across all key metrics.”